Drug intelligence / Profile preview

GlutaZorb

Development stage: Unknown
Lead developer: All American Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

GlutaZorb is a dietary supplement and nutraceutical developed by Dr. Jeff Golini and marketed by All American Pharmaceutical and EFX Sports. It consists of a proprietary, enzymatically modified form of the amino acid glutamine, produced through a patented pH-correct, buffered fermentation process. This technology is designed to enhance the stability of glutamine in liquid solutions and improve its delivery to the bloodstream by protecting it from degradation in the digestive tract. GlutaZorb is primarily indicated for sports nutrition and athletic performance, where it is used to support muscle recovery, immune system function, and digestive health during periods of intense physical training and metabolic stress.

Brand names: GlutaZorb
Other names: GlutaZorb®

Beyond the preview

Go deeper on GlutaZorb.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GlutaZorb.

Explore the full profile